Speaker (2021 JPM WEEK)

Speakers

Topic: Opening Speech & China Biotech Innovation

Jeffrey Zhang Summit Chair, CHBD

Founder of PROMED; Former Vice President of Wuxi AppTec; Successively served as the head of new business development of Pfizer China, director of Johnson & Johnson China’s strategic market.

Topic: Cross-border Licensing Annual review

  Sean Jiang CFA & CEO & Founder, YAFO Capital

20+ years Wall Street banking & investment experience with Roth Capital, Xiangcai Securities, etc. Former China GM of ISI Group (Evercore).

Topic: Japan Market Opportunity for Chinese Pharmas

Steve Engen Founder&President, Renexes LLC

20+ years of Japanese and American pharmaceutical industry experience, brought over dozen US pharmaceutical products to the Japanese market.

Topic: Bio-century Commercial section- the evolution of china pharma market

Tina Hou Global Partner, Mckinsey

Tina leads the new-product-launch work in McKinsey’s Pharmaceutical & Medical Products Practice in China and has extensive experience in launch excellence issues.

Topic: Global Transaction Experience – MNC Perspective

Cynthia Wang    BD&Licensing Director, BioInnovation Asia, Les Laboratories SERVIER

Cynthia brings with her over 19 years of Healthcare/pharmaceutical industrial experience in China. Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities

Topic: Swiss Biotech Innovation

Michael Altorfer     CEO, Swiss Biotech Association

Dr. Michael Altorfer has more than 20 years of experience in the life science industry compromising both big pharma and smaller biotech organizations.

Topic: Booming biologics: business and investment impact on Med tech

Jimmy Jin    Senior Director of BD   Becton Dickinson & Company China

Jimmy Jin is leading business development for BD China. Prior to joining BD, he has worked as director of business development in Thermo Fisher China and a senior consultant in Bain & Company. He and his team have completed 20+ investment and collaboration projects in the sector of medical device, IVD, bio-tech, and analytical instrument.

Topic: From pipeline to topline, from China to the world.

Jiaxi Xu    Chief Analyst, Industrial Securities

Dr. Xu was graduated from School of Life Sciences of Fudan University. He has rich research experience in pharma and insurance institutions. He led the team to win the No. 1 Best Analyst of New Wealth.

Topic: Cell therapy industry and outlook

Wenjun Sun    SVP BD, JW Therapeutics

Wen-jun Sun has over 20 years of broad leadership experience at Merck ( MSD ) at the US global headquarter and MSD China, in R&D, Manufacturing, Finance, Business development and partnership management.

Topic: Innovative Opportunities and Challenges of Orphan Drugs in China

 James Xue CEO & Founder, CANbridge

Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company focused on oncology and rare disease.

 Alan Yan Co-founder, Chairman, CEO, Seprogenix

25 years+ of senior management experience in MNC;Served as the head of Sanofi Pasteur’s business operations in China, General Manager of Actelion China;Held senior management positions in Sandoz China and Merck Serono China;Management experience covers clinical development and regulatory matters, BD, marketing, business channel management and operations.

Topic: China Biotech, Lovely Bubble, Lovely Cream

Sam Ma   Co-Founder, CHBD

Sam has over 25 years experience in China, EU, US, Japan and India Life science industry, including AIDEA Pharma Co. Ltd, Urihk Pharma, GSK China and Global and Eisai China.

Topic: Investment Strategy for the Pharmaceutical Industry: Innovation + Import Substitution Lead the Great Era of Pharmaceuticals

Xiangyang Du    Chief Analyst, the pharmaceutical industry, South West Securities

Mr. Du was a doctoral candidate of the Chinese Academy of Sciences, received Master of Science degree from the Chinese Academy of Sciences. He has 6-year research experience in the pharmaceutical industry.

Topic: Pharma BD in China

Kui Wang       Secretary General, CHBD

Mr. Wang has rich experience in pharma Business Development for more than 20 years with a record more than 50 M&A and licensing transactions. He worked in Saiya Consulting, Eisai Pharma, Leo Pharma, and Eddingpharm.

Topic: Intellectual Property Structures in Research Collaborations – Pitfalls and Solutions

Julian Thurston    CEO&Founder , Theobald Associates

Julian Thurston has been “top ranked” for commercial lifesciences since the leading legal directories (such as Chambers, Legal 500 and PLC) began covering the sector, and in Chambers Global has been ranked one of the top 10 lawyers globally for commercial lifesciences for over 10 years.

Topic: Clinical Transformation of Cartilage  3D BioPrinting

Huimin Chen    Founder&CEO, SinoBioPrint

Dr. Huimin Chen is the founder and CEO of Huaxia SinoBioPrint (Shanghai) Biotech Ltd. and Jiangyin StemEasy Biotech Ltd.  He focuses on the research, development and clinical application of cartilage 3D bioprinted and stem cell regenerative medicine in orthopedics, sports medicine and plastic surgery.

Topic: Expanding the Frontiers of Neuroscience in China

June Yan   CEO, Neurofront Therapeutics

20 years of experience working in the pharma industry in a variety of markets including the United States, China and Asia. June had multiple key leadership roles in pharma MNCs and biotech companies including 17 years in Eli Lilly, Celgene and BeiGene.

Disruptive approach to treat CNS diseases via the gut-brain axis: autism, a case study

David H Donabedian   Co-founder & CEO, Axial Therapeutics

Since Axial’s launch in November 2016, David has raised significant capital from top-tier VCs, including Taiho, Seventure, Longwood and Domain Associates and assembled a renowned advisory and scientific board and established the company as a leader in the gut-brain-axis.


View Agenda

<span>%d</span> bloggers like this: